Navigation Links
New NIH grant helps MU scientist get to the heart of muscular dystrophy
Date:12/6/2010

Children with Duchenne muscular dystrophy (DMD) face a future of rapidly weakening muscles, which usually leads to death by respiratory or cardiac failure before their 30th birthday. While researchers are hopeful that gene therapy could eventually evolve into an effective treatment, few have targeted the heart of the problem as much as Dongsheng Duan, PhD.

Duan hopes a new $2.1 million grant he received from the National Institutes of Health will help him develop a treatment that prevents heart muscles from weakening as a result of DMD. As many as 40 percent of patients with the inherited disorder die from heart failure because their weakened cardiac muscles can't pump enough blood to sustain life.

Children with DMD, which is often seen in boys, experience weakening of both skeletal muscle and heart muscle due to a defective gene for dystrophin, a type of muscle protein. Researchers have developed a synthetic dystrophin gene that has shown to be effective in treating skeletal muscle, but Duan's findings published in the journal Molecular Therapy show that cardiac muscle requires different treatment. In fact, tests in an animal model have shown that treating skeletal muscle alone while leaving cardiac muscle untreated can lead to serious complications: Stronger skeletal muscles mean patients can be more physically active, which requires a stronger heart to pump blood throughout the body.

"We've demonstrated that the gene therapy that works for the skeletal muscle doesn't necessarily work for the heart," Duan said. "If we want a more comprehensive treatment, we cannot ignore how the disease affects cardiac muscle."

Duan's lab has analyzed data on thousands of patients with DMD to identify common patterns in deletions on the dystrophin gene that could have led to heart-specific muscle weakness. Now the researcher is developing a new synthetic gene that he hopes will comprehensively treat muscles weakened by DMD.

"We're developing this gene based on what we already know about skeletal muscle, so it will not only be perfectly functional for skeletal muscle but also therapeutic for heart muscle," said Duan, a Margaret Proctor Mulligan Distinguished Professor in Medical Research in MU's Department of Molecular Microbiology and Immunology.

Duan plans to evaluate the newly developed gene in dystrophic mouse and dog models. With funding from additional NIH grants, Duan's team is developing viral vectors for carrying the most important parts of the therapeutic genes to diseased muscle cells. The therapy-carrying viruses will be injected directly into the blood system or the muscles. Following therapy, researchers will perform a series of tests to evaluate the strength of the heart muscle and the effect of the treatment.

"Researchers are more advanced in their understanding of Duchenne muscular dystrophy when it comes to skeletal muscle, but cardiac and skeletal muscle need to be simultaneously treated in patients," Duan said. "This is just the beginning of research on the heart muscle."

While still being tested in labs, Duan's proposed therapy gives hope to parents like Robert McDonald, MD, of Jefferson City, Mo. His son Mark was diagnosed with DMD when the boy was 2 years old. Dr. McDonald now serves on the board of directors and the therapeutics committee for Parent Project Muscular Dystrophy, the largest nonprofit organization focused on DMD. Parent Project has also awarded funds for Duan's research.

"He is one of the most valuable people trying to find a solution for DMD," McDonald said. "Parents like me are looking to scientists like him to someday help our children grow up to be men, and hopefully old men."


'/>"/>

Contact: Natalie Fieleke
fieleken@health.missouri.edu
573-884-7541
University of Missouri School of Medicine
Source:Eurekalert

Related biology news :

1. $4.3 million DARPA grant enables development of biological and chemical threat detector
2. New Scripps Florida scientist awarded pair of unconventional grants
3. VaxTrac Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
4. Aeras awarded €11.7 million ($16 million) grant from Dutch government
5. Unconventional idea for antiviral contraceptive gel wins Gates Foundation grant
6. Undergraduates low-cost ultrasound system wins Gates Foundation grant
7. $12 million grant to probe root causes of heart failure
8. Landenberger Foundation awards grant to Scripps Florida scientist to study HIV
9. NSF awards $3.75 million grant to New York Plant Genome Consortium for the creation of BigPlant v1.0
10. NSF awards grants for research on coupled natural and human systems
11. Universities receive grants to study climate change decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... , ... April 29, 2016 , ... ... personalized pain medicine, is excited to announce the launch of the Proove ... health studies, volunteerism, and education to promote the use of personalized medicine for ...
(Date:4/29/2016)... Marietta, GA (PRWEB) , ... April 29, 2016 ... ... marketer of medical devices used in spinal surgical procedures, today announced the completion ... an enhanced value proposition for current and future customers and partners. Kohlberg ...
(Date:4/29/2016)... New York , April 29, 2016 /PRNewswire/ ... report published by Transparency Market Research "Separation Systems ... Size, Share, Growth, Trends, and Forecast 2015 - ... was valued at US$ 10,665.5 Mn in 2014 ... of 6.8% from 2015 to 2023 to reach ...
(Date:4/29/2016)... ... April 29, 2016 , ... During ... transform technology into a viable company, CereScan’s CEO, John Kelley, joined other Denver ... recognized leader and mentor in the Denver area business community, shared his top ...
Breaking Biology Technology: